Top Markets
#1 ORDI ORDI +75.07%
#2 tomiNet tomiNet +42.74%
#3 1000SATS (Ordinals) 1000SATS (Ordinals) +37.39%
#4 SATS (Ordinals) SATS (Ordinals) +36.77%
#5 pippin pippin +33.93%
#6 Axelar Axelar +33.55%
#7 Swarms Swarms +25.58%
#8 Bio Protocol Bio Protocol +23.17%
#9 Walrus Walrus +20.25%
#10 Zerebro Zerebro +20.22%
Coin of the day
ORDI ORDI
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rangering i aksjer #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aksjekurs
$0.00047446
Markedsverdi
$82.80
Endring (1 dag)
0.00%
Endring (1 år)
-98.16%
Land
FR
Handel Neovacs S.A. (ALNEV)

Kategori

Healthcare
P/S-forhold for Neovacs S.A. (ALNEV)
P/S-forhold per April 2026 TTM: 0.00
Ifølge Neovacs S.A. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0.00. Ved slutten av 2023 hadde selskapet et P/S-forhold på 1.32K.
P/S-historikk for Neovacs S.A. fra 2007 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
2026 (TTM) 0.00 -100.00%
2024 485.89 -63.15%
2023 1.32K 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.54 707,620.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.38 1,874,940.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.47 1,094,520.00%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.65 1,330,780.00%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
15.23 3,045,540.00%
NL